Impact of Prior Use of an Androgen Receptor‐Axis‐Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration‐Resistant Prostate Cancer